Product Description
Perampanel is a potentially broad-spectrum antiepileptic drug with a novel mechanism of action that may be a useful addition for patients with epilepsy with various seizure types. The availability of novel antiepileptic drugs for epilepsy treatment enables more individualized treatment for these patients. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29953584/)
Mechanisms of Action: AMPA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovakia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location:
Company CEO: Haruo Naito
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Czech Republic, Denmark, France, Germany, India, Japan, Spain, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Lennox Gastaut Syndrome|Seizures
Phase 2: Epilepsy|Glioma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04497142 |
2P50CA165962-06A1 | P2 |
Completed |
Glioma|Seizures |
2023-05-16 |
25% |
2023-08-15 |
|
NCT04015141 |
E2007-G000-236 | P2 |
Recruiting |
Epilepsy |
2027-04-06 |
12% |
2025-06-24 |
|
JapicCTI-173536 |
JapicCTI-173536 | P3 |
Active |
Lennox Gastaut Syndrome |
2022-01-28 |
|||
NCT06450236 |
PR/BE/23/228 | P1 |
Completed |
Epilepsy |
2023-11-26 |
2024-06-11 |
Primary Endpoints|Treatments |
|
2023-507794-17-00 |
E2007-G000-236 | P2 |
Recruiting |
Epilepsy |
2026-12-23 |
2025-05-02 |
Treatments |
|
NCT06450223 |
PR/BE/23/229 | P1 |
Completed |
Epilepsy |
2023-09-20 |
2024-06-11 |
Primary Endpoints|Treatments |
|
2007-006191-11 |
Not applicable | P3 |
Active, not recruiting |
Seizures |
2019-12-03 |
2025-07-04 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/20/2024 |
News Article |
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences |
|
07/24/2024 |
News Article |
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada |
|
07/22/2024 |
News Article |
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024 |
|
05/30/2024 |
News Article |
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE® |